CION Ameerpet
DLBCL is a fast-growing B-cell lymphoma — and one of the more treatable aggressive lymphomas. This guide explains what it is, its symptoms, how it is diagnosed and staged, its subtypes, and how CION's lymphoma team plans care.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) — it accounts for roughly a third of all NHL diagnoses. It is an aggressive, or fast-growing, B-cell lymphoma: a cancer of the B-lymphocytes, the white blood cells that normally produce antibodies to fight infection. When these cells become malignant, they multiply quickly and can build up in lymph nodes or in organs outside the lymphatic system.
The name itself describes what a pathologist sees. "Diffuse" means the abnormal cells spread out and erase the normal, orderly structure of a lymph node; "large" means the cancer cells are big compared with normal lymphocytes. Because DLBCL grows fast, it usually needs prompt treatment — but, encouragingly, that same rapid growth makes it responsive to therapy, and it is one of the aggressive lymphomas most often treated with the intent to cure.
This guide walks through the symptoms, how DLBCL is diagnosed and staged, its important subtypes, and how it is treated. For the wider context of lymphoma care, start at our lymphoma hub; to plan treatment locally, see Lymphoma Treatment in Hyderabad, or meet the team on our best lymphoma doctors in Hyderabad page.
DLBCL is the most common non-Hodgkin lymphoma worldwide, making up around 30–40% of all NHL cases. Despite being classed as an aggressive, fast-growing cancer, it is also one of the aggressive lymphomas most likely to be cured — a majority of people treated with modern immunochemotherapy achieve long-term remission. (Source: figures summarised in NCCN and ESMO B-cell lymphoma guidelines; outcomes vary by individual.)
Because DLBCL is aggressive, symptoms often appear and worsen over weeks rather than months. The classic sign is a fast-growing, painless swelling — but DLBCL can also start outside the lymph nodes.
These symptoms have many ordinary causes and are usually not lymphoma. But a lump that keeps growing, or B symptoms lasting more than a couple of weeks, should be checked promptly. Speak to a CION lymphoma specialist if this describes you.
Aggressive lymphoma rewards speed, accuracy and a coordinated team. CION brings the diagnostics, treatment and supportive care together under one plan.
DLBCL is not one disease. We arrange cell-of-origin testing (germinal-centre vs activated B-cell) and MYC / BCL2 molecular testing on your biopsy — the details that separate ordinary DLBCL from double-hit / high-grade B-cell lymphoma and shape the plan.
Antibody (immunotherapy) infusions, multi-agent chemotherapy and precision radiation (IMRT) are delivered directly by CION. Stem-cell transplant and CAR T-cell therapy, when needed, are coordinated through accredited partner facilities.
Every DLBCL is reviewed by a multidisciplinary tumour board — haematology, medical and radiation oncology together — so the plan reflects your stage, IPI risk and molecular profile, not a one-size template.
We provide a free written second opinion on your biopsy and PET-CT, and structured survivorship follow-up after treatment. For prognosis specifics, see our DLBCL survival & prognosis page.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a DLBCL diagnosis, want to understand your subtype and stage, or need a second opinion before treatment starts? CION's lymphoma team is here.
Confirming DLBCL — and pinning down its exact subtype — follows a step-by-step pathway. CION delivers the biopsy coordination, bone-marrow examination, molecular testing and review directly.
Diagnosis needs a tissue sample. For an aggressive lymphoma, the preferred approach is an excisional biopsy — removing a whole affected lymph node — so the pathologist can study the full tissue architecture, which a thin needle sample often cannot show. The tissue is examined with immunohistochemistry to confirm B-cell markers such as CD20, which also identifies the target for antibody therapy later.
On the biopsy tissue, further tests establish the cell-of-origin (germinal-centre B-cell vs activated B-cell) and check for MYC, BCL2 and BCL6 rearrangements. These are testing concepts, not drugs — they tell the team whether the lymphoma is ordinary DLBCL or a high-grade "double-hit" pattern that behaves more aggressively. NCCN and ESMO guidelines expect this information at diagnosis.
Staging usually uses a PET-CT scan and often a bone-marrow examination, giving a stage from 1 (one node region) to 4 (widespread). Blood tests, including LDH, and an assessment of your general fitness feed into the International Prognostic Index (IPI), which combines age, stage, LDH, performance status and extranodal sites to estimate risk and guide the intensity of treatment.
DLBCL is really a family of related aggressive B-cell lymphomas. Getting the exact category right — from tissue and molecular testing — is what lets the team tailor treatment. The main distinctions are:
| Category | What defines it | Why it matters |
|---|---|---|
| Germinal-centre B-cell (GCB) | Cell-of-origin resembling germinal-centre cells | Generally a more favourable outlook among DLBCL subtypes |
| Activated B-cell (ABC) / non-GCB | Cell-of-origin resembling activated B-cells | Tends to behave less favourably; influences trial and treatment choices |
| Double-hit / high-grade B-cell | MYC plus BCL2 and/or BCL6 rearrangements | More aggressive; usually treated more intensively — see the double-hit lymphoma page |
| Primary mediastinal B-cell | Arises in the chest, often in younger adults | A distinct entity with its own approach — see primary mediastinal B-cell lymphoma |
| Primary CNS lymphoma | Confined to the brain, spine or eyes | Needs a specialised, CNS-directed plan — see primary CNS lymphoma |
| Transformed lymphoma | Aggressive DLBCL arising from an indolent lymphoma | Common when follicular lymphoma transforms to aggressive disease |
Subtyping follows current WHO/ICC classifications and NCCN/ESMO guidance. The category is decided by a haematopathologist on tissue and molecular testing, not by a scan alone.
Not all fast-growing B-cell lymphomas that look like DLBCL are the same. About 5–10% carry rearrangements in both MYC and BCL2 (and/or BCL6) — the "double-hit" or high-grade B-cell lymphomas — which behave more aggressively and are usually treated more intensively. That is precisely why NCCN and ESMO recommend testing for MYC and BCL2 on every new DLBCL biopsy: identifying them early changes the treatment plan. (Source: NCCN and ESMO B-cell lymphoma guidelines.)
Because DLBCL is aggressive, treatment usually begins soon after diagnosis and is given with the intent to cure. The plan depends on the stage, IPI risk, subtype and your overall health, and every case is reviewed by CION's multidisciplinary tumour board first. The main building blocks are:
The standard first-line treatment combines an anti-CD20 monoclonal antibody (immunotherapy that targets the CD20 marker on B-cells) with multi-agent chemotherapy, given over several cycles. CION delivers both the antibody infusions and the chemotherapy directly. The exact regimen names and cycle counts are individualised — we discuss those in consultation and on the Lymphoma Treatment in Hyderabad page rather than online.
For early-stage or bulky DLBCL, radiation therapy (IMRT) may be added after chemotherapy to consolidate the response, shaping the beam precisely to the involved area while sparing healthy tissue. CION delivers precision radiation directly.
For higher-risk disease — certain sites, high LDH, or high-grade features — additional treatment may be given to protect or treat the central nervous system. This is decided case by case at the tumour board.
If DLBCL returns or does not respond fully, second-line chemotherapy is used, and for fitter patients this may be consolidated with high-dose therapy and an autologous stem-cell transplant — coordinated by CION through accredited partner facilities. Newer CAR T-cell therapy is likewise coordinated by referral to accredited centres for selected patients. Our relapsed or refractory DLBCL page explains these next steps in detail.
DLBCL is one of the aggressive lymphomas most often treated successfully. Across published international series, a majority of people are alive at five years — figures commonly quoted in the region of 60–70%, and higher for lower-risk, early-stage disease (per NCCN and ESMO-referenced data). For comparison, Hodgkin lymphoma five-year survival is generally quoted around 80–90%. These are population averages; the outlook for any individual depends on stage, age, IPI score and molecular features, and varies from person to person.
The International Prognostic Index (IPI) is the main tool used to estimate risk, and the response seen on the PET-CT after treatment is one of the strongest indicators of a durable remission. For a fuller, subtype-by-subtype breakdown, see our dedicated DLBCL survival & prognosis page. We avoid quoting CION-specific survival statistics online — we discuss your individual outlook honestly in consultation.
DLBCL sits within a wider family of B-cell lymphomas. If you're researching a specific subtype, these companion guides cover the full cluster:
An aggressive lymphoma diagnosis moves quickly, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Explore the best lymphoma hospital in Hyderabad, request your free second opinion, or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if cell-of-origin and MYC/BCL2 testing has not yet been arranged on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.DLBCL is the most common type of non-Hodgkin lymphoma (NHL). It is an aggressive (fast-growing) B-cell lymphoma — a cancer of the B-lymphocytes, a kind of white blood cell that normally fights infection. "Diffuse" describes how the abnormal cells spread out and erase the normal architecture of a lymph node when seen under the microscope, and "large" describes the size of the cancerous cells. Because it grows quickly, DLBCL usually needs prompt treatment — but its speed also makes it one of the more treatable aggressive lymphomas. For the wider picture, see our lymphoma hub, and to plan care in the city, our Lymphoma Treatment in Hyderabad page.
The most common sign is a rapidly enlarging, painless lump — usually a swollen lymph node in the neck, armpit or groin — that grows over weeks rather than months. Because DLBCL can also start outside the lymph nodes (extranodal disease), symptoms sometimes come from an affected organ, such as abdominal fullness, chest pressure or bowel changes. Many people also notice so-called "B symptoms": unexplained fever, drenching night sweats and weight loss. Fatigue and itching can occur too. These signs are common to many harmless conditions, so they are not proof of lymphoma — but a lump that keeps growing, or B symptoms lasting more than two weeks, should be assessed promptly. Speak to a CION haematology-oncology specialist if these apply to you.
DLBCL is one of the aggressive lymphomas that is often curable, even at advanced stages — which is unusual and encouraging for a fast-growing cancer. Across published international series, a majority of people with DLBCL are alive at five years, with figures commonly quoted in the region of 60–70% and higher for lower-risk, early-stage disease (per NCCN and ESMO-referenced data). The outlook depends on stage, age, the International Prognostic Index (IPI) score, and molecular features such as cell-of-origin and MYC/BCL2 status. Figures are population averages and vary by individual. For a fuller breakdown, see our DLBCL survival & prognosis page.
Diagnosis needs a biopsy — ideally removal of a whole affected lymph node (excisional biopsy) so a pathologist can study the full tissue structure. A small needle sample is often not enough for an aggressive lymphoma. The tissue is examined with immunohistochemistry to confirm B-cell markers such as CD20, and further tests establish the cell-of-origin (germinal-centre vs activated B-cell) and check for MYC and BCL2 rearrangements. Staging then uses a PET-CT scan and usually a bone-marrow examination to map how far the disease has spread (stages 1–4). CION delivers biopsy coordination, bone-marrow exams and molecular testing directly. Learn more about the tests on our Lymphoma Treatment in Hyderabad page.
Because DLBCL is aggressive, treatment usually starts soon after diagnosis and is given with the intent to cure. The backbone is a combination of immunochemotherapy — an anti-CD20 monoclonal antibody paired with multi-agent chemotherapy — sometimes with radiation therapy (IMRT) added for bulky or localised disease. The number of cycles depends on stage and risk. CION delivers chemotherapy, antibody (immunotherapy) infusions, radiation, molecular testing and supportive care directly, with every case reviewed by a multidisciplinary tumour board. Specific regimen names and doses are individualised — we discuss these on the Lymphoma Treatment in Hyderabad page rather than online. To meet the team, see our best lymphoma doctors in Hyderabad.
Most people treated for DLBCL do not relapse, but if the lymphoma returns or does not respond fully (relapsed/refractory disease), there are still effective options. Second-line treatment often uses a different chemotherapy combination, and for suitable, fitter patients this may be followed by high-dose therapy with an autologous stem-cell transplant — coordinated by CION through accredited partner facilities rather than delivered in-house. Newer cellular therapies such as CAR T-cell treatment are also coordinated by referral to accredited centres for selected patients. Choosing the right next step depends on how the disease behaved first time, your fitness and molecular features. Our dedicated relapsed or refractory DLBCL page walks through what happens next.
Some aggressive B-cell lymphomas that look like DLBCL carry rearrangements in two or three key genes — MYC together with BCL2 and/or BCL6. These are classified separately as high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements — often called "double-hit" or "triple-hit" lymphoma. They tend to behave more aggressively than ordinary DLBCL and are usually treated more intensively, which is exactly why molecular testing for MYC and BCL2 is done routinely at diagnosis. Identifying them early changes the treatment plan. Read more on our double-hit / high-grade B-cell lymphoma page.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.